Article info

Direct delivery of an investigational cell therapy in patients with Parkinson’s disease: an interim analysis of feasibility and safety of an open-label study using DBS-Plus clinical trial design

Authors

  1. Correspondence to Dr Craig G van Horne; craigvanhorne{at}uky.edu
View Full Text

Citation

Quintero JE, Slevin JT, Gurwell JA, et al
Direct delivery of an investigational cell therapy in patients with Parkinson’s disease: an interim analysis of feasibility and safety of an open-label study using DBS-Plus clinical trial design

Publication history

  • Received March 16, 2022
  • Accepted June 13, 2022
  • First published July 15, 2022.
Online issue publication 
July 15, 2022
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.